Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiplatelet drugs

G A Fitzgerald1, E A Meagher

  • 1Department of Medicine and Experimental Therapeutics, University College, Dublin, Ireland.

European Journal of Clinical Investigation
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histocompatibility antigens and haemochromatosis in Ireland.

Irish journal of medical science·2016
Same author

Neurogenic aspects of essential hypertension in man.

Irish journal of medical science·2016
Same author

Molecular clocks and the human condition: approaching their characterization in human physiology and disease.

Diabetes, obesity & metabolism·2015
Same author

A metabolomic study of adipose tissue in mice with a disruption of the circadian system.

Molecular bioSystems·2015
Same author

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Atherosclerosis·2015
Same author

The Concise Guide to PHARMACOLOGY 2013/14: overview.

British journal of pharmacology·2014
Same journal

Pacemaker Status and 5-Year Mortality After TAVI: A Sex-Specific Analysis.

European journal of clinical investigation·2026
Same journal

Causal Effects of Time-Varying Treatments: The G-Formula.

European journal of clinical investigation·2026
Same journal

Improving Scientific Research: Renegotiated Principles of Science, Proposals, Failures, and Successes.

European journal of clinical investigation·2026
Same journal

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.

European journal of clinical investigation·2026
Same journal

Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.

European journal of clinical investigation·2026
Same journal

Circulating Human Epididymis Protein 4 Predicts 10-Year Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease.

European journal of clinical investigation·2026
See all related articles

Aspirin is proven safe and effective for preventing vascular occlusion after a platelet-related event. Promising new drugs, like glycoprotein IIb/IIIa antagonists, are being developed to compete with aspirin.

Area of Science:

  • Cardiovascular medicine
  • Pharmacology
  • Thrombosis research

Background:

  • Aspirin is a cornerstone therapy for secondary prevention of vascular occlusion.
  • Its established efficacy has limited the development of alternative antiplatelet agents.
  • Thromboxane antagonists have shown limited success as aspirin competitors.

Purpose of the Study:

  • To review the compelling evidence for aspirin's safety and efficacy in secondary prevention.
  • To discuss the impact of aspirin on the development of competing antiplatelet therapies.
  • To highlight the potential of glycoprotein IIb/IIIa antagonists as the next generation of antiplatelet drugs.

Main Methods:

  • Literature review of clinical trials and pharmacological studies.
  • Analysis of market trends and drug development pipelines.

Related Experiment Videos

  • Evaluation of safety and efficacy data for antiplatelet agents.

    • Main Results:

    • Overwhelming evidence supports aspirin's role in preventing platelet-dependent vascular occlusion.
    • Aspirin's success has created a high bar for new drug development.
    • Glycoprotein IIb/IIIa antagonists represent a significant advancement in antiplatelet therapy.

    Conclusions:

    • Aspirin remains a highly effective and safe option for secondary vascular event prevention.
    • Further research is needed to optimize the delivery and safety of novel agents like glycoprotein IIb/IIIa antagonists.
    • The development of effective competitors to aspirin is crucial for advancing cardiovascular care.